Literature DB >> 24399721

Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.

Xiao-Jing He1, Ling-Yan Jian, Xiao-Lin He, Yan Wu, Yuan-Yuan Xu, Xiao-Jie Sun, Li-Yan Miao, Li-Mei Zhao.   

Abstract

BACKGROUND: This study examined the significant association between carbamazepine (CBZ)-induced Stevens-Johnson Syndrome (SJS)/toxic epidermal necrolysis (TEN) and HLA-B*15:02 in epilepsy patients of Han ethnicity living in northeastern China.
METHODS: CBZ-SJS/TEN patients and CBZ-tolerant control patients were genotyped for HLA-B*15:02 by PCR amplification using sequence-specific primers. Patients then were evaluated for HLA genotypes using PCR with sequence-based typing.
RESULTS: Eight of 35 CBZ-SJS/TEN patients carried HLA-B*15:02 (22.9%) versus 2 of 125 in CBZ-tolerant control patients (OR = 18.222, 95% CI = 3.662-90.662, p = 0.000). Our results suggest that HLA-B*15:02 is necessary but is not sufficient to produce SJS/TEN following CBZ treatment among Han individuals from northeastern China. Other HLA alleles, including A*33:03, B*58:01, C*03:02, DQB1*03:03, and DRB1*07:01 may be associated weakly with CBZ-SJS/TEN.
CONCLUSIONS: Our results are not consistent with previous studies reporting a strong association between HLA-B*15:02 and CBZ-SJS/TEN among individuals from southern, southwestern, and central China. Other genes may be more tightly associated with CBZ-SJS/TEN. Screening for HLA-B*15:02 still may be recommended for patients in northeastern China before starting CBZ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24399721     DOI: 10.1016/s1734-1140(13)71483-x

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  11 in total

1.  External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy.

Authors:  Guigao Lin; Kuo Zhang; Yanxi Han; Jiehong Xie; Jinming Li
Journal:  J Clin Lab Anal       Date:  2017-04-25       Impact factor: 2.352

2.  Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors:  Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

3.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 4.  Developing pharmacogenetic screening methods for an emergent country: Vietnam.

Authors:  Dinh Van Nguyen; Christopher Vidal; Hieu Chi Chu; Sheryl van Nunen
Journal:  World Allergy Organ J       Date:  2019-06-06       Impact factor: 4.084

5.  Diagnostic Utility of Human Leukocyte Antigen B*15:02 Screening in Severe Carbamazepine Hypersensitivity Syndrome.

Authors:  Youssef Moutaouakkil; Badr Adouani; Yahia Cherrah; Jamal Lamsaouri; Yassir Bousliman
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

Review 6.  Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.

Authors:  Chih-Jung Chang; Chun-Bing Chen; Shuen-Iu Hung; Chao Ji; Wen-Hung Chung
Journal:  Front Pharmacol       Date:  2020-07-02       Impact factor: 5.810

Review 7.  Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics.

Authors:  Therdpong Tempark; Shobana John; Pawinee Rerknimitr; Patompong Satapornpong; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

8.  Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype.

Authors:  Rika Yuliwulandari; Erna Kristin; Kinasih Prayuni; Qomariyah Sachrowardi; Franciscus D Suyatna; Sri Linuwih Menaldi; Nuanjun Wichukchinda; Surakameth Mahasirimongkol; Larisa H Cavallari
Journal:  Pharmacogenomics       Date:  2017-10-20       Impact factor: 2.533

Review 9.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

10.  Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia.

Authors:  Hui Xue; Wenping Xiang; Yichuan Yu; Guorong Liu; Yi Chong; Jiying Zhou
Journal:  Drug Des Devel Ther       Date:  2018-04-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.